A huge pharmaceuticals company pays a smaller rival millions not tosell a generic version of the drug giant’s product.Is it a smart business deal, or an illicit ploy to restraincompetition?
That’s one of the questions increasingly being asked as the powerfulbrand-name prescription drug industry fights to protect its profitsfrom smaller, generic drug makers vying to cash in by offering cheaperversions of popular drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
